The CDC recommends that all individuals aged 75 and older, as well as adults aged 60 and older who are at risk for severe RSV ...

GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the efficacy and safety of ...

Patients hospitalized for respiratory syncytial virus (RSV) are highly likely to require home care post-discharge.

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

Respiratory Illness season is right around the corner and experts are urging parents to take action to protect their newborns ...

COVID-19, influenza and RSV are the main threats between October and May. There are vaccines for all three viruses, so you ...

In 2023, the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) recommended ...

Respiratory syncytial virus (RSV) remains the top cause of hospitalization among young children, leading to respiratory ...

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

Study compares immediate post-discharge care requirements for respiratory syncytial virus (RSV), influenza, acute myocardial ...

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...